Soft tissue venous malformation

Soft tissue venous malformations (VMs) are benign, low-flow vascular malformations composed of ectatic, dysmorphic venous channels with deficient smooth muscle support.[1][2] They arise from somatic mosaic mutations—most commonly in TIE2/TEK or PIK3CA—that disrupt endothelial signaling and vascular morphogenesis during fetal development.[1][3][4] VMs are present at birth and grow proportionately with the patient; they do not proliferate or involute.[5][6] In the oral and maxillofacial region, VMs characteristically present as compressible, blue-purple soft tissue masses, and phleboliths within the lesion are considered pathognomonic on imaging.[1][6] Management ranges from observation and compression to sclerotherapy, surgical excision, or targeted medical therapy, depending on lesion extent and symptoms.[1]

The International Society for the Study of Vascular Anomalies (ISSVA) classification—first adopted in 1996 and most recently updated in 2025—divides vascular anomalies into vascular tumors (endothelial proliferation) and vascular malformations (developmental defects with quiescent endothelium).[2][7] VMs are classified as simple, slow-flow vascular malformations and are named by their predominant vessel type.[7][8]

• Current preferred term: venous malformation (VM).[7]
• Accepted subtypes: sporadic common VM, familial cutaneomucosal VM (CMVM), glomuvenous malformation (GVM).[7][9]
• Obsolete terms: "cavernous hemangioma" and "soft tissue hemangioma" remain in widespread clinical use but are inaccurate; they conflate a developmental malformation with a true vascular neoplasm and should be avoided. The persistent misuse of "hemangioma" for VMs has been shown to delay appropriate treatment and occasionally lead to inappropriate therapy.[5][9][10]

• Prevalence: VMs are the most common type of vascular malformation, with an estimated prevalence of approximately 1% and an incidence of roughly 1 in 10,000 live births.[5][11]
• Head and neck predilection: Approximately 40%–60% of all VMs occur in the head and neck region.[1][2]
• Oral and maxillofacial sites: The muscles of mastication (masseter, temporalis), lip, tongue, and buccal and oropharyngeal mucosa are the most commonly involved sites. The cheek is the single most frequent location in head and neck series.[1][5][12]
• Age and sex: VMs are present from birth, though they may not become clinically apparent until childhood or puberty. No consistent sex predilection has been established. More than 60% of VMs reportedly progress during adolescence.[1][5][12]
• Sporadic vs. familial: Over 90% of VMs are sporadic and unifocal. Familial forms—including autosomal dominant CMVM (TIE2 mutations) and GVM (GLMN mutations)—are uncommon.[1][9]

Presentation and symptoms

VMs typically present as soft, nonpulsatile masses with blue or purple discoloration of the overlying skin or mucosa; color varies with lesion depth, ranging from undetectable to deep purple.[1][5] Superficial oral mucosal VMs appear as compressible, blue-purple nodules or plaques on the lip, tongue, buccal mucosa, or palate. Deeper lesions in the muscles of mastication may present as painless facial swelling with normal overlying skin.[12]

Examination findings

• Compressibility: VMs characteristically empty with manual pressure and refill when released; they engorge with dependency or Valsalva maneuver.[1][5][12]
• Phleboliths: Palpable as firm, mobile nodules within the lesion; they represent calcified intraluminal thrombi and can be exquisitely painful.[1][6]
• Fluctuation with position: Lesion size increases with dependent positioning and elevated central venous pressure, distinguishing VMs from lymphatic malformations.[1]

Tempo and progression

VMs grow proportionately with the patient. Accelerated expansion may occur with puberty, pregnancy, trauma, infection, or incomplete treatment.[1] Progressive venous stasis leads to localized intravascular coagulation (LIC), characterized by elevated D-dimer and, in severe cases, low fibrinogen and thrombocytopenia.[6][13]

Complications and red flags

• Intermittent pain and swelling from thrombophlebitis and phlebolith formation.[1]
• Airway compromise when VMs involve the tongue, floor of mouth, or pharynx.[1][5]
• Functional impairment: trismus (masseteric or pterygoid involvement), dysphagia, or speech difficulty.
• Cosmetic disfigurement from discoloration and contour irregularity.[1]
• Risk of progression to disseminated intravascular coagulation (DIC) during surgery or sclerotherapy in patients with pre-existing LIC.[14][15]

Soft tissue VMs are predominantly extrabony lesions; their radiographic manifestations on dental imaging are therefore indirect, centering on the detection of phleboliths and secondary effects on adjacent osseous structures.

Location and distribution

VMs in the oral and maxillofacial region most commonly involve the soft tissues of the cheek, lip, tongue, and masticator space.[1][12] On panoramic radiography, the lesion itself is not directly visible as a discrete radiolucency or radiopacity within bone. Instead, the hallmark finding is the presence of phleboliths—round or ovoid radiopaque bodies projected over the soft tissues of the affected region.[16]

Phleboliths: appearance and significance

Phleboliths are calcified thrombi that form within the ectatic venous channels due to blood stasis.[6][16] On panoramic radiography and other dental radiographs:

• They appear as small, well-defined, round to ovoid radiopacities, often with a characteristic concentric laminated ("target" or "onion-skin") pattern.[16]
• Multiple phleboliths may be scattered across the region of the malformation.[16]
• They are considered pathognomonic for VMs among vascular anomalies and are a key finding that should prompt further investigation.[6][17]
• Phleboliths must be differentiated from sialoliths, calcified lymph nodes, tonsilloliths, and other soft tissue calcifications; their round laminated morphology and location outside salivary gland ducts or lymph node chains aid distinction.[16]

On CBCT, phleboliths are more precisely localized within the soft tissue mass, and their concentric laminated architecture is better resolved than on two-dimensional projections. CBCT also allows assessment of whether the malformation has produced secondary pressure effects on adjacent bone.

Periphery and shape

When a VM abuts or exerts pressure on the jaws, the adjacent cortical bone may show smooth, scalloped remodeling rather than aggressive destruction. The lesion itself lacks a defined bony margin because it is a soft tissue process. On cross-sectional imaging, the soft tissue component appears as an ill-defined or lobulated mass of heterogeneous density.[18]

Internal architecture

The soft tissue mass is predominantly of soft tissue density on CT-based imaging, with phleboliths appearing as discrete high-density foci within the lesion.[18] On contrast-enhanced CT, VMs demonstrate initial inhomogeneous enhancement with progressive filling—a pattern reflecting slow blood flow through ectatic channels.[1][18] This progressive enhancement pattern helps distinguish VMs from lymphatic malformations, which enhance only at the periphery.[1]

Effects on teeth and adjacent structures

• Tooth displacement or mobility: Occasionally observed when VMs involve the alveolar soft tissues or exert mass effect on the alveolar process.
• Root resorption: Not a characteristic feature; its presence should raise consideration of alternative diagnoses.
• Cortical remodeling: Smooth pressure remodeling of the buccal or lingual cortex may occur with large or long-standing lesions but frank cortical destruction is uncommon.

Growth pattern and extent

VMs expand slowly and may infiltrate along tissue planes, involving multiple anatomic compartments (e.g., extending from the masticator space into the parapharyngeal space or palate).[16] Cross-sectional imaging is essential for delineating the full three-dimensional extent, particularly when the lesion involves deep spaces not assessable on panoramic radiography.

Recognized variants

• Intraosseous (central) vascular malformations of the jaws are rare and represent a distinct entity from soft tissue VMs. Central vascular malformations produce multilocular or poorly defined radiolucencies within bone, may show continuity with the mandibular canal, and carry a risk of life-threatening hemorrhage with biopsy or extraction. Their imaging features differ substantially from the soft tissue phlebolith pattern described above.[19][20]

MRI

MRI is the gold standard for characterizing soft tissue VMs and delineating their full extent.[5][12][21]

• T2-weighted sequences: VMs are characteristically hyperintense on T2-weighted and STIR images, reflecting the fluid-filled ectatic channels. Fat suppression improves lesion conspicuity.[1][6]
• T1-weighted sequences: VMs are iso- to hypointense on T1; areas of T1 hyperintensity may indicate hemorrhage, thrombus, or fat.[6]
• Contrast enhancement: Inhomogeneous enhancement initially, with progressive increased enhancement on delayed images—a hallmark that distinguishes VMs from lymphatic malformations, which enhance only at the periphery.[1][21]
• Phleboliths appear as foci of low signal on all sequences.[21]
• Extent mapping: MRI defines involvement of deep structures (muscles, neurovascular bundles, airway) and is essential for treatment planning.[5][21]

Ultrasonography

Ultrasound serves as a useful initial imaging modality, particularly in superficial lesions.[6][21]

• VMs appear as heterogeneous, hypoechoic lesions with anechoic tubular vascular channels.[6][21]
• Phleboliths appear as hyperechoic foci with posterior acoustic shadowing.[6]
• Color Doppler flow may be absent or minimal due to very slow flow; compression and release maneuvers can elicit detectable flow.[1][6]
• Compressibility of the lesion under the transducer is a characteristic finding.[6]

Medical CT

Contrast-enhanced CT demonstrates the progressive enhancement pattern and is superior to MRI for detecting calcified phleboliths.[18] CT has a limited role in routine VM evaluation but may be useful when MRI is contraindicated or for assessing bony involvement.[22]

Soft tissue VMs in the oral and maxillofacial region must be distinguished from other vascular anomalies and soft tissue masses that present as compressible or blue-purple lesions. The presence of phleboliths, compressibility, slow-flow hemodynamics, and characteristic MRI signal narrow the differential considerably.

The highest-risk diagnostic pitfall is misidentifying a soft tissue VM as an infantile hemangioma, which leads to expectant management (awaiting involution that will not occur) or inappropriate pharmacotherapy such as propranolol.[5][10] When clinical and imaging findings are equivocal, biopsy with immunohistochemistry (GLUT-1, smooth muscle α-actin) can confirm the diagnosis, though biopsy of vascular lesions carries bleeding risk and should be performed with caution.[6][24]

Microscopic findings

VMs are composed of irregularly dilated, thin-walled vascular channels of variable caliber dispersed within connective tissue, fat, or skeletal muscle.[12][25] The channels are lined by a single layer of flattened endothelial cells with quiescent morphology.[9][12] The vessel walls characteristically show an irregularly deficient or absent smooth muscle layer (tunica media), which accounts for the progressive dilation and compressibility of the lesion.[2][9] Luminal contents may include blood, organizing thrombi, and calcified phleboliths.[25]

Immunohistochemistry

• CD31 and CD34: Positive, confirming endothelial lineage.[26]
• GLUT-1: Negative, which is the key marker distinguishing VMs from infantile hemangiomas (GLUT-1 positive).[24][26]
• Smooth muscle α-actin: Sparse and patchy staining of the vessel wall, in contrast to glomuvenous malformations, which show dense layers of glomus cells with strong α-actin positivity.[9]
• WT-1: Typically negative, supporting classification as a malformation rather than a vascular tumor.[26]

Radiologic-pathologic correlation

The ectatic, thin-walled channels correspond to the slow-flow, compressible mass seen clinically and the T2-hyperintense signal on MRI. Phleboliths seen on radiographs and CT correlate with intraluminal calcified thrombi. The deficient smooth muscle layer explains the progressive dilation and positional engorgement observed clinically and on imaging.

Molecular findings

Sporadic VMs harbor somatic activating mutations in TIE2/TEK (approximately 40%–50% of cases) or PIK3CA (approximately 10%–15%), both converging on the PI3K/AKT/mTOR signaling pathway.[1][3][4] Familial cutaneomucosal VMs carry germline TIE2 mutations with a somatic second hit.[27] These molecular findings are clinically relevant because they provide the rationale for targeted therapy with sirolimus (an mTOR inhibitor).[28][29]

Workup and referral

• Clinical diagnosis is based on history (present since birth, proportionate growth, no involution) and examination (compressible, blue, nonpulsatile mass).[1][5]
• MRI with contrast is the standard for defining lesion extent and planning treatment.[5][21]
• Coagulation studies (D-dimer, fibrinogen, CBC) should be obtained for large or extensive VMs to assess for LIC, particularly before any invasive procedure.[13][15]
• Multidisciplinary evaluation at a vascular anomalies center is recommended for complex or extensive lesions.[6][21]

Treatment

• Conservative management: Observation, compression garments, NSAIDs, and low-dose aspirin (up to 81 mg daily) for mild symptoms and thrombophlebitic pain. Low-molecular-weight heparin may be added for refractory pain or significant LIC.[1][15]
• Sclerotherapy: The mainstay of treatment for symptomatic VMs. Sodium tetradecyl sulfate (as foam), ethanol, bleomycin, and polidocanol are commonly used agents. Multiple sessions are typically required. Symptom improvement is reported in 54%–80% of patients, though complete resolution is uncommon. Airway protection is critical for oral and oropharyngeal lesions due to post-procedural swelling.[1][2][30][31][32]
• Surgical excision: Favored for well-circumscribed, localized VMs that spare vital structures, and when critical structures (e.g., facial nerve) are in close proximity to the lesion, making sclerotherapy risky. Preoperative sclerotherapy or embolization with n-butyl cyanoacrylate can reduce intraoperative hemorrhage.[1]
• Nd:YAG laser: Useful for superficial mucosal VMs of the oral cavity, pharynx, and larynx; may be combined with sclerotherapy.[1][12]
• Sirolimus (rapamycin): Indicated for refractory pain, swelling, and coagulopathy in extensive VMs not amenable to procedural intervention. The VASE phase III trial demonstrated clinical improvement in 85% of patients, with recurrence of symptoms in 54% after treatment cessation.[1][29]

Recurrence and prognosis

VMs are not curable in the traditional sense; treatment aims to control symptoms and reduce lesion volume. Recurrence or re-expansion after sclerotherapy is common, and repeated sessions are often necessary.[31][33] Surgical excision of well-defined lesions offers the best chance of durable local control but carries risk of hemorrhage and injury to adjacent structures.[1][33] Incomplete treatment, trauma, and hormonal changes can spur re-expansion.[1]

Syndromic associations

• Blue rubber bleb nevus syndrome (Bean syndrome): Multiple cutaneous and visceral VMs caused by somatic double TIE2 mutations; gastrointestinal VMs may cause chronic bleeding requiring aggressive management.[3][25]
• Familial cutaneomucosal VM (CMVM): Autosomal dominant, caused by germline TIE2 mutations; multifocal small blue mucocutaneous lesions that increase in number over time.[9]
• Glomuvenous malformation (GVM): Caused by GLMN mutations; clinically and histologically distinct from common VM and requires differentiation because treatment response and prognosis differ.[9]

Coagulopathy considerations

Elevated D-dimer is found in approximately 42%–58% of VM patients, with concurrent hypofibrinogenemia in 6%–10%.[13] Preoperative hematology consultation and prophylactic anticoagulation are recommended for patients with extensive VMs and laboratory evidence of LIC undergoing surgery or sclerotherapy.[14][15]

Hormonal triggers

Puberty and pregnancy are recognized triggers for VM expansion and symptom exacerbation, which is relevant for counseling adolescent and reproductive-age patients.[1]